English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background  The aim of this study was to evaluate the association between  CYP2A13  polymorphisms and lung cancer susceptibility using the HapMap database.    Methods  A case‐control analysis of 532 subjects with lung cancer and 614 controls with no personal history of the disease was performed. The tag SNPs rs1645690 and rs8192789 for  CYP2A13  were selected, and the genetic polymorphisms were confirmed experimentally through real‐time PCR, cloning, and sequencing assay.    Results  SNP frequency in this study was consistent with the HapMap Project database of Han‐Chinese and lung cancer risk was associated with  CYP2A13  polymorphisms in non‐smokers.  CYP2A13  shares a 93.5% identity with  CYP2A6  in the amino acid sequence and the homologous sequences may interfere with the study of SNPs of  CYP2A13 .    Conclusions   CYP2A13  may be a potential key metabolic enzyme gene in the carcinogenesis of lung cancer in non‐smokers. The common polymorphisms of  CYP2A13  may be candidate biomarkers for lung cancer susceptibility in Han‐Chinese.

HapMap‐based study: CYP2A13 may be a potential key metabolic enzyme gene in the carcinogenesis of lung cancer in non‐smokers